Jacobs Bruce N. 4

What Happened

• Bruce N. Jacobs, Chief Financial Officer of Kymera Therapeutics (KYMR), exercised stock options on 2026-06-02 to acquire 12,653 shares at an exercise price of $2.08 per share, paying $26,318 in cash. The Form 4 also reports the corresponding conversion/disposition of the derivative instrument (12,653 shares at $0), which reflects the option being converted into common shares. Footnote: the underlying options were fully vested and exercisable.

Key Details

• Transaction date: 2026-06-02
• Exercise (acquired): 12,653 shares @ $2.08 = $26,318 (code M: option exercise)
• Derivative conversion/disposition: 12,653 shares @ $0 (reflects conversion of option into shares)
• Shares owned after transaction: not disclosed in this Form 4
• Footnote: F1 — shares underlying this stock option are fully vested and exercisable
• Filing date: 2026-06-03 (appears timely; no late filing flag)

Context

• This was an option exercise (insider acquired shares by paying the exercise price), not an open-market purchase or sale. The separate $0 “disposition” line is a common reporting convention showing the option was converted into shares, not a sale of the acquired stock. No immediate sale or cashless exercise was reported on this Form 4.